Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells

Molecular Cancer Research

Volumn 7, Issue 8, 2009, Pages 1378-1389

  Ko, Jen Chung ^a   Ciou, Shih Ci ^b   Jhan, Jhih Yuan ^b   Cheng, Chao Min ^b   Su, Ying Jhen ^b   Chuang, Show Mei ^c   Lin, Szu Ting ^b   Chang, Chia Che ^c   Lin, Yun Wei ^b  

^a Hsinchu Hospital   (Taiwan)

^b NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ERLOTINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAD51 PROTEIN; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL GROWTH; CELL LINE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RAD51 RECOMBINASE; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 69449106495     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0051     Document Type: Article

References (50)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
2. Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993;68:162-165 (Pubitemid 23178571)
3. Arteaga CL. EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. J Clin Oncol 2003;21:289-91s.
4. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000;60 Suppl 1:15-23, discussion 41-112 (Pubitemid 30828934)
5. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002;110:669-672 (Pubitemid 35283957)
6. Shibata T, Kawano T, Nagayasu H, et al. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol 1996;17:168-175 (Pubitemid 26151481)
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132 (Pubitemid 41058344)
8. Felip E, Rosell R. Clinical experience with erlotinib in non-small-cell lung cancer. Drugs Today (Barc) 2006;42:147-156 (Pubitemid 44917510)
9. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama 2003;290:2149-2158 (Pubitemid 37432975)
10. Kokubo Y, Gemma A, Noro R, et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 2005;92:1711-1719 (Pubitemid 40756483)
11. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003;9:2316-2326 (Pubitemid 36687658)
12. Haaf T, Golub EI, Reddy G, Radding CM, Ward DC. Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes. Proc Natl Acad Sci U S A 1995;92:2298-2302
13. Baumann P, West SC. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci 1998;23:247-251 (Pubitemid 28343368)
14. Buchhop S, Gibson MK, Wang XW, Wagner P, Sturzbecher HW, Harris CC. Interaction of p53 with the human Rad51 protein. Nucleic Acids Res 1997;25:3868-3874 (Pubitemid 27420495)
15. Slupianek A, Hoser G, Majsterek I, et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 2002;22:4189-4201
16. Bello VE, Aloyz RS, Christodoulopoulos G, Panasci LC. Homologous recombinational repair vis-a-vis chlorambucil resistance in chronic lymphocytic leukemia. Biochem Pharmacol 2002;63:1585-1588 (Pubitemid 34457997)
17. Tsuzuki T, Fujii Y, Sakumi K, et al. Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci U S A 1996;93:6236-6240 (Pubitemid 26230288)
18. Ohnishi T, Taki T, Hiraga S, Arita N, Morita T. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem Biophys Res Commun 1998;245:319-324
19. Taki T, Ohnishi T, Yamamoto A, et al. Antisense inhibition of the RAD51 enhances radiosensitivity. Biochem Biophys Res Commun 1996;223:434-438 (Pubitemid 26245585)
20. Carlomagno F, Burnet NG, Turesson I, et al. Comparison of DNA repair protein expression and activities between human fibroblast cell lines with different radiosensitivities. Int J Cancer 2000;85:845-849 (Pubitemid 30131476)
21. Djuzenova C, Muhl B, Schakowski R, Oppitz U, Flentje M. Normal expression of DNA repair proteins, hMre11, Rad50 and Rad51 but protracted formation of Rad50 containing foci in X-irradiated skin fibroblasts from radiosensitive cancer patients. Br J Cancer 2004;90:2356-2363 (Pubitemid 38961900)
22. Maacke H, Jost K, Opitz S, et al. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 2000;19:2791-2795 (Pubitemid 30339230)
23. Yoshikawa K, Ogawa T, Baer R, et al. Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas. Int J Cancer 2000;88:28-36. (Pubitemid 30677415)
24. Qiao GB, Wu YL, Yang XN, et al. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 2005;93:137-143
25. Ko JC, Ciou SC, Cheng CM, et al. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. Carcinogenesis 2008;29:1448-1458
26. Ko JC, Hong JH, Wang LH, et al. Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells. Mol Cancer Ther 2008;7:3632-3641
27. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137
28. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181 (Pubitemid 46316032)
29. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-183 (Pubitemid 32458157)
30. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-185
31. Kortylewski M, Heinrich PC, Kauffmann ME, Bohm M, MacKiewicz A, Behrmann I. Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells. Biochem J 2001;357:297-303. (Pubitemid 32642930)
32. 1 cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated: upregulation of p27(Kip1). J Biol Chem 2001;276:2686-2692
33. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-354 (Pubitemid 40637826)
34. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-370 (Pubitemid 38579482)
35. Perng RP, Yang CH, Chen YM, et al. High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer 2008;62:78-84.
36. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:3908-3914 (Pubitemid 44078074)
37. Ahmed SM, Salgia R. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology 2006;11:687-692 (Pubitemid 44581431)
38. Achille M, Gallegos-Ruiz M, Giaccone G, Soria JC. Response to erlotinib in first-line treatment of non-small-cell lung cancer in a White male smoker with squamous-cell histology. Clin Lung Cancer 2006;8:214-216 (Pubitemid 44896395)
39. Mladenov E, Anachkova B, Tsaneva I. Sub-nuclear localization of Rad51 in response to DNA damage. Genes Cells 2006;11:513-524
40. Vispe S, Cazaux C, Lesca C, Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res 1998;26:2859-2864 (Pubitemid 28297517)
41. Takenaka T, Yoshino I, Kouso H, et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 2007;121:895-900.
42. Sak A, Stueben G, Groneberg M, Bocker W, Stuschke M. Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines. Br J Cancer 2005;92:1089-1097 (Pubitemid 40546674)
43. Hannay JA, Liu J, Zhu QS, et al. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther 2007;6:1650-1660 (Pubitemid 46954032)
44. Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE, Lingen MW. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol 2006;28:1113-1119
45. Ko JC, Hong JH, Wang LH, Lin YW. The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, Iressa(R)) and benzo[a]pyrene in human lung cancer. Exp Cell Res 2008;314:1881-1891.
46. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005;65:3328-3335 (Pubitemid 40524617)
47. Russell JS, Brady K, Burgan WE, et al. Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 2003;63:7377-7383 (Pubitemid 37413479)
48. Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T. The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer 2003;105:472-479 (Pubitemid 36578549)
49. Helfrich BA, Raben D, Varella-Garcia M, et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 2006;12:7117-7125 (Pubitemid 44974512)
50. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139 (Pubitemid 38637993)